Takeda Pharmaceutical Co Ltd (HAM:TKD)
€ 25.66 0.01 (0.04%) Market Cap: 41.10 Bil Enterprise Value: 67.01 Bil PE Ratio: 22.79 PB Ratio: 0.95 GF Score: 75/100

Neurocrine Biosciences Inc and Takeda Pharmaceutical Co Ltd Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders Transcript

Jun 16, 2020 / 12:00PM GMT
Release Date Price: €33.41 (+3.18%)
Operator

Good day, everyone, and welcome to today's Neurocrine Biosciences company update. (Operator Instructions) Please note, this call may be recorded. (Operator Instructions) It is my pleasure to turn the program over to Todd Tushla.

Todd Tushla
Neurocrine Biosciences, Inc. - VP of IR

Thanks, Leo. Good morning, everyone, and thank you for joining our call today on short notice to discuss the collaboration we announced earlier this morning with Takeda.

During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings.

Joining me on the call today is Kevin Gorman, our Chief Executive Officer; Kyle Gano, our Chief Business Development and Strategy Officer; Eiry Roberts, our Chief Medical Officer; Matt Abernethy, our Chief Financial Officer; Eric Benevich, our Chief Commercial Officer; and Jaz Singh, our Vice President of Clinical Development. During this call,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot